Evaluating Expected Medication Costs and Budget Impact of Systemic Therapies for Unresectable/Metastatic Melanoma

Li, Z; Whisman, Tyler; Tang, Jackson; Grzegorzewski, Kris; Quadri, Syed M.; Mahmood, Syed; Qiu, Ying

doi:10.1016/j.jval.2016.03.1554

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 In the United States, although from the perspective of private health plans rather than public services, important financial consequences of introducing target therapy in clinical practice have been pointed out, especially because of drug costs. 30 Flávia de Miranda Corrêa et al…”

Section: 535mentioning

confidence: 99%

Terapia-alvo versus dacarbazina no tratamento de primeira linha do melanoma avançado não cirúrgico e metastático: análise de impacto orçamentário na perspectiva do Sistema Único de Saúde, 2018-2020*

Corrêa

Guerra

Fernandes

et al. 2019

Epidemiologia e Serviços de Saúde

View full text Add to dashboard Cite

Objective: to estimate the incremental budget impact of target therapy for first-line treatment of advanced non-surgical and metastatic melanoma compared to dacarbazine treatment. Methods: budget impact analysis, from the Brazilian National Health System (SUS) perspective; based on demographic data and incidence estimates, the population over a three-year time horizon (2018-2020) was delimited and the direct medical costs were estimated; the reference scenario was treatment with dacarbazine, and the alternative scenarios were target therapy with vemurafenib, dabrafenib, vemurafenib + cobimetinib and dabrafenib + trametinib; uncertainty assessment was conducted through scenario analysis. Results: the incremental budget impact ranged from R$ 451,867,881.00 to R$ 768,860,968.00, representing 0.70 to 1.53% of total SUS annual outpatient drugs expenditure; in best and worst scenario, results ranged from R$ 289,160,835.00 to R$ 1,107,081,926.00. Conclusion: the use of target therapy compared to dacarbazine implies an excessive impact on the budget, this bring unfovorable to its possible incorporation.

show abstract

Section: 535mentioning

confidence: 99%